Podcasts about dlb

En este episodio de DLB, repasamos la emocionante final de la Copa del Rey, con todos los detalles del partido, los goles clave y lo que significa para el equipo campeón. También hablamos de lo más reciente de la NBA, con análisis de los playoffs y los jugadores que están marcando la diferencia.Además, calentamos motores con la previa del próximo Gran Premio de Fórmula 1, repasamos favoritos, circuitos y como va el standing hasta el momento. Y por si fuera poco, te traemos un resumen del Draft de la NFL con los picks más importantes y donde la audiencia debe tener la vista esta próxima temporada.Todo esto y mucho más en un episodio lleno de acción deportiva. ¡No te lo pierdas!

Hoy es jueves de DLB, y en este episodio analizamos la histórica celebración del Clásico de Madrid en Puerto Rico, exploramos un poco de la historia del deporte en la isla y destacamos a nuestros exponentes en ascenso. Luego, nos metemos de lleno en la Fórmula 1, repasando lo último en la parrilla, las sorpresas de la temporada y el cambio drástico de Liam Lawson por Yuki Tsunoda en Red Bull: ¿merecido o una jugada arriesgada? Además, discutimos otras noticias del mundo deportivo que no te puedes perder. ¡Dale play y únete a la conversación!

En esta edición de DLB, Neftalí y Keyraliz se enfocan en las grandes ligas que inician en nuestra isla. Analizamos el arsenal de cada equipo en el BSN, las fortalezas y debilidades de los jugadores clave que buscan el campeonato. También hablamos del Clásico Mundial de Béisbol, los equipos clasificados y las expectativas de los fanáticos. Además, tocamos un poco sobre la Liga de Béisbol Superior Doble A y otros temas. ¡No te lo pierdas, dale play!

Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep disorders, and cognitive dysfunction, there are no good diagnostics to identify DLB and effective treatments. Cognition Therapeutics' lead drug candidate, an oral treatment, has shown promise in protecting neurons from the toxic effects of the pathological proteins involved in Alzheimer's and DLB. Lisa explains, "This company started in 2007, so we've had a long number of years to burnish our mission. One of the things we say is we're the beginning of the end of neurologic disorders and the start of hope for an improved future for patients. So Alzheimer's disease, in particular, has been long studied with little success, and in the last few years, we've seen some successes with monoclonal antibodies. There are a number of other approaches in clinical trials, but we have recently generated very positive data in two different trials with an oral once-a-day drug." Tony elaborates, "Lewy body dementia or dementia with Lewy bodies is a disease very much related to Parkinson's disease that's believed to be, in part, caused by pathological levels of a certain protein called alpha synuclein and particularly small oligomers of misfolded alpha synuclein." "And in Alzheimer's disease, this is largely a cognitive memory disorder as it presents. So, those two diseases are very different. Now, the idea of treating them with a single drug is somewhat unique to what we have here at Cognition Therapeutics. So our company started around the idea of developing therapies for Alzheimer's disease, and our lead molecule CT1812 or zervimesine was developed out of a screening assay where we were looking for molecules that could protect neurons or brain cells from the toxicities of this pathological amyloid protein. So, we identified CT1812 and have been developing it."  #CognitionTherapeutics #BrainHealth #DementiaCare #LewyStrong #Livingwithlewy #Alzheimers #EndAlz #Alzheimersdisease #DLBAwareness #NeurodegenerativeDisease #Dementia #DementiaWithLewyBodies  cogrx.com Download the transcript here

Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep disorders, and cognitive dysfunction, there are no good diagnostics to identify DLB and effective treatments. Cognition Therapeutics' lead drug candidate, an oral treatment, has shown promise in protecting neurons from the toxic effects of the pathological proteins involved in Alzheimer's and DLB. Lisa explains, "This company started in 2007, so we've had a long number of years to burnish our mission. One of the things we say is we're the beginning of the end of neurologic disorders and the start of hope for an improved future for patients. So Alzheimer's disease, in particular, has been long studied with little success, and in the last few years, we've seen some successes with monoclonal antibodies. There are a number of other approaches in clinical trials, but we have recently generated very positive data in two different trials with an oral once-a-day drug." Tony elaborates, "Lewy body dementia or dementia with Lewy bodies is a disease very much related to Parkinson's disease that's believed to be, in part, caused by pathological levels of a certain protein called alpha synuclein and particularly small oligomers of misfolded alpha synuclein." "And in Alzheimer's disease, this is largely a cognitive memory disorder as it presents. So, those two diseases are very different. Now, the idea of treating them with a single drug is somewhat unique to what we have here at Cognition Therapeutics. So our company started around the idea of developing therapies for Alzheimer's disease, and our lead molecule CT1812 or zervimesine was developed out of a screening assay where we were looking for molecules that could protect neurons or brain cells from the toxicities of this pathological amyloid protein. So, we identified CT1812 and have been developing it."  #CognitionTherapeutics #BrainHealth #DementiaCare #LewyStrong #Livingwithlewy #Alzheimers #EndAlz #Alzheimersdisease #DLBAwareness #NeurodegenerativeDisease #Dementia #DementiaWithLewyBodies  cogrx.com Listen to the podcast here

Je m'entretiens avec la rappeuse basée à Montréal Kelzk, qui vient de sortir son EP de sept chansons DLB, son quatrième projet en quatre ans. Avec la présence de son amie et collaboratrice Princesse, nous avons discuté de la réception du public et des médias vis-a-vis son tout nouvel opus, son processus d'écriture, de sa place dans l'industrie musicale montréalaise et française ainsi que de ses différentes manières de montrer son identité via sa musique.    TVE - Kelzk (DLB) LMS- Kelzk (DLB) CHIEN- Kelzk (DLB) YATA- Kelzk (DLB) AGOGO- Kelzk (DLB) ELLE EST FRESH- Kelzk (DLB) PRESSION- Kelzk (DLB)

We're back with Part Two of our special highlights podcasts from the International Lewy Body Dementia Conference in Amsterdam! This time, host Dr Sterre de Boer (Alzheimer's Centre Amsterdam) leads the discussion with a fantastic panel of experts:

In this episode, I review the four main mimics of Parkinson's disease, also called the Parkinson's Plus syndromes. These are multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). I explore the clinical manifestations, investigations, and treatments of these disorders, highlighting such striking features as autonomic dysfunction in MSA, unusual eye movements in PSP, fluctuating cognition in DLB, and alien hand syndrome with CBD. I also illustrate the patient perspectives of the disorders with such illness memoirs as those of Kimberly Bohannon titled The Beautiful Destruction of My Life, of Bill Sydnor titled Living Day by Day With MSA, that of Claire Verney titled Notes of a Love Song, that of Steve Dagnell titled You, Me & PSP, and that of Evelyn Walsh titled Parkinson's Plus: A Woman's Struggle Battling Alien Movements.

Lewy body dementia is a common cause of cognitive impairment in older adults but is often subject to significant delays in diagnosis and treatment, increasing the burden on patients and family caregivers. Understanding key features of the disease and use of biomarkers will improve recognition. In this episode, Allison Weathers, MD, FAAN, speaks with James E. Galvin, MD, MPH, author of the article “Lewy Body Dementia,” in the Continuum December 2024 Dementia issue. Dr. Weathers is a Continuum® Audio interviewer associate chief medical information officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Galvin is a professor of neurology at the University of Miami Miller School of Medicine in Miami, Florida. Additional Resources Read the article: Lewy Body Dementia Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Weathers: This is Dr Allison Weathers. Today I'm interviewing Dr James Galvin, author of Lewy body dementias from the December 2024 Continuum issue on dementia. Welcome to the podcast, Dr Galvin. Please introduce yourself to our audience.  Dr Galvin: Thank you, Allison. My name is Jim Galvin. I'm a neurologist, a professor of neurology at the University of Miami Miller School of Medicine. Dr Weathers: We're so happy to have you with me today. Thanks, Jim, for your time. And as you highlight right from the start in your really outstanding and comprehensive overview of this really complex topic, even though Lewy body dementia is the second most common cause of neurodegenerative dementia, it often goes unrecognized in clinical practice, resulting in really potentially lengthy diagnostic delays. So, this is a really important article for a neurologist and an important topic for our listeners. So, I'm thrilled we're having this conversation today. While I traditionally start by asking the authors what they feel is the most important clinical message of their article, I would love to actually start a step earlier in this conversation with you. Can you start us off by explaining what's actually meant when we say Lewy body dementia? Dr Galvin: Great. So, you know, I think this is a, this is an interesting concept. So, we're really talking about two diseases that have a shared common pathology. So, Parkinson's sees dementia and dementia with Lewy bodies. So, their shared pathology is a Lewy body and that's why they're often grouped together as the Lewy body dementias. And then there's arguments back and forth as to whether these are distinct diseases or sort of two ends of the same candle burning in different directions. So, Parkinson's dementia is a lot like what it sounds like. So, if someone has Parkinson's disease, then at some point later they develop a dementia. And so back in the 1800's when Parkinson's disease was like first described as an entity, we basically felt that cognition wasn't affected. But we now know that's not true. And so most patients with Parkinson's do have some cognitive symptoms and a large proportion of them will eventually develop dementia. Perhaps up to 80% of Parkinson's patients will develop a dementia. The flip side is the dementia with Lewy body picture. And these are people who present primarily with a cognitive behavioral syndrome that may or may not have parkinsonism. So, they will sometimes have bradykinesia. They rarely have a rest tremor. And so, these are the people that are very much in the delayed diagnosis group. The Parkinson's dementia is more whether the clinician is checking their cognition as part of their annual visit. The flip side is that the people with DLB are often misdiagnosed early on, but together, this is Lewy body dementia, which is the most common disease that many people have never heard of. Dr Weathers: That's a great tagline, I think, for the whole article and for this concept. So now that that we're all on the same page about what's meant when we use that the term, what would you want our listeners to walk away with as their one key takeaway from our conversation today? Dr Galvin: Well, I think the article makes several key points, but I think if I put those all together into a single key point, it would really be that the Lewy body dementias are underrecognized, they're underdiagnosed, yet it is very possible to make the diagnosis using the standardized clinical criteria. They're very, very, very specific. They lack a little bit in sensitivity. So, because other diseases sometimes can look like this, but they're really quite specific. So, if you're confident clinically that the person has Lewy body dementia, you're probably going to be right. And in today's world, we have tests available to help confirm our diagnosis. The world is changing. We can make these diagnosed with much more confidence and we have confirmatory diagnosis laboratory tests that can help us. Dr Weathers: I want to talk more about the diagnosis in one minute, but first, how common actually are dementia with Lewy bodies and Parkinson's disease dementia? Dr Galvin: That's a great question. I think one of the challenges, of course, we really don't know how many people have any disease because it's going to largely rely on how well people code the diseases in the medical record. So, if you look at the most common cause of dementia in the United States, it's really dementia not otherwise specified, right? But we believe it to be the second most common cause of dementia. The Lewy Body Dementia Association, about a decade ago, started to try to develop some estimates. So, we have an estimate about how many people roughly have Parkinson's disease and that about 80% of those individuals would go on to develop dementia. And we know from the dementia population that about 40% of those individuals coming to autopsy have Lewy bodies. So, when you start to put that all together, you can get a reasonable estimate of how many people likely have the disease. And then that can be expanded on an annual basis, just like the Alzheimer's Association uses, by extrapolating those estimates onto the census data. So, we estimate right now there are about 1.4 to 1.6 million Americans who are living with Lewy body dementia. That's less than the 6.8 million people who have Alzheimer's disease, but more than a lot of other common diseases. So, if you think about, again, I said before, it's the most common disease no one's ever heard of. You know, there are about a million people who have multiple sclerosis. There are about eight hundred thousand people who have a stroke. There are about seven hundred thousand people who have a brain tumor. There are two hundred and fifty thousand people who have muscular dystrophy. There are twelve thousand people who have ALS. But I think if you stopped clinicians or people in the street and say have you ever heard of ALS or muscular dystrophy, they would say yes. If you ask them if they've heard of Lewy body dementia, they would say no.  Dr Weathers: That's an excellent point. And I know over the years I think there's been some increased awareness. I think sadly with some of the celebrities that have been impacted, I think that did a lot to raise awareness. But I think you're right that it's still so less commonly recognized by the lay public, by non-neurologists, than so many other diseases that you mentioned. And I think that leads back well into my next question into something that we've already mentioned just a few times already in our short conversation, this unfortunate and very common delay in the diagnosis. Why? And you mentioned earlier that there are these, you know, clinical criteria, these now ancillary tests. So, what makes the diagnosis so challenging? What aspects in particular do you think that neurologists find to be the most challenging in diagnosing patients? What trips us up?  Dr Galvin: So, there's an old analogy, right, that, you know, if you'll be three blind men to an elephant and each of them are touching a different part of the elephant, they'll each think it's something different. So because Lewy body dementia has so many different diverse kind of symptoms, it would really depend on who's seeing the patient first. So, if a person presents predominantly with a memory cognitive disorder and they go see someone who specializes in memory disorders, they're highly likely to be called Alzheimer's disease. If they present predominantly with the movement problem, they're going to see a movement disorder person and be called Parkinson's disease. If they present with a behavioral disorder, they're going to go see a psychiatrist. Then they'll get diagnoses like, you know, geriatric schizophrenia or bipolar disease or major depressive disorder. If they present with the constitutional symptoms, which are very common and drive patients absolutely batty. So chronic constipation, REM sleep disorder, runny nose, you know, heat intolerance, urinary frequency, obstipation, and you know, they're going to be called all sorts of things. So, if you start thinking about this, who do you show up with first is going to guide how fast you can get a diagnosis. So, we interviewed at point over a thousand caregivers and what we found was there was about an eighteen month delay after seeing five to six doctors for the majority of patients, of which Lewy body dementia was misdiagnosed about 75% of the time for the initial diagnosis.  Dr Weathers: Wow, what a sobering statistic. And you spoke about the criteria and some of the ancillary tests. What can really help, do you think, kind of mitigate or prevent this misdiagnosis? What is your approach in your own patients?  Dr Galvin: Well, I think like every good clinician, not starting off with a preconceived notion of what the person has and trying to collect all the valuable information. So, one of the things I highlighted in the article was, while there are diagnostic criteria and people can follow diagnostic criteria, the truth is at your fingertips. You don't always sit and think about whether someone meets diagnostic criteria. So, in the first table in the article, we tried to really then put all the different common symptoms into buckets, right? Because people present like that. They say, well, I have this and I have this and I have this and I have this. Well, then you can start to think about, well, they have a cognitive symptom that's predominantly executive attention or visual perceptual in nature. And gee, they have constipation and heat intolerance and they say they can't smell quite as well as they once did, right, and they're having some disturbance in their sleep with excessive daytime sleepiness. Now you can start to say, well, even though that didn't fit the core and suggestive criteria, the fact is that spectrum of symptoms makes it much easier to begin to make a diagnosis. And so, it's investigative work. A lot of neurology is still investigative work. The old days, they used to say, we knew everything but could do nothing, but now we know everything and can do something about it. And so, I think it's really important that we try to apply this information in clinically useful ways. That was part of the gist of putting this Continuum article together was to try to present it not just as listing the diagnostic criteria, because you can get that anywhere, but how do you actually apply it in clinical practice? Dr Weathers: That's a great point. And that table that you referenced was really fantastic. And I know I say this a lot, but they're true. So, you know, many of the tables, the reference to Continuum, one I will certainly kind of come back to again, again, as an excellent point of care tool. So, I know in, in preparing for today and reading more about, about you and your areas of research that one of your particular areas of focus and expertise is in healthcare disparities, especially in the early detection of neurodegenerative dementias. What is the greatest inequity or disparity that you see in the diagnosis and treatment of patients with Lewy body dementia?  Dr Galvin: So, there's a couple things that are that are really interesting. So first, unlike Alzheimer's disease, which tends to be a little bit more female predominant, the Lewy body dementias are male predominant. It's about 1.6 men for everyone woman. So, it's going to be a different presentation. It's going to be largely men and their caregivers are largely going to be their spouses. So, you're going to see sort of a different person looking, you know, staring on the other side of the table to you. It's going to be largely a male. And the other thing that's really interesting is that almost all of the series, case series, case reports, clinical papers are in predominantly white populations. So, this lends to some interesting things. So, you know, is the disease less common in African Americans and other minority populations or are we just really bad at ascertaining the disease? You know, many of the case reports in Alzheimer's disease include African Americans. In fact, we know that African Americans may be at a twofold increased risk of developing Alzheimer's disease compared to nonHispanic whites, probably due to vascular risk factors. But in case series of Lewy body dementia, almost all the patients are non-Hispanic white. There also seems to be a higher risk in Asian populations, and in fact, some of the very earliest case reports were from Japan. Is this a case ascertainment problem or is this really a disparity in how the disease presents? And I think those are really important questions that still need to be asked. I know as researchers, we struggle to try to develop cohorts that could help us understand that. I would say in my twenty five years of seeing these patients, I would say the large percentage of them, and I've seen a lot of them, have been no-Hispanic white.  Dr Weathers: So, so definitely more research needed in this very important area. So, moving on to somewhat of a personal question, I always, this is such an honor. I always talk about that I get to have this time to sit down with the authors of these outstanding articles and learn not only more about their subjects, but about them as people. I had shared during my last interview that my paternal grandmother had Alzheimer's disease, and unfortunately also my maternal grandmother actually did as well. In preparing for this, I had listened to one of your previous interviews and learned that you also have a personal connection that led you to this subspecialty with several family members impacted. How has this connection inspired your research and your interactions with your patients?  Dr Galvin: Yeah, I mean, so my personal connection was that my maternal grandfather had Lewy body dementia. So, I grew up in a two family home in New Jersey. My grandparents lived on the second floor. We lived on the first floor. I wass very close to my grandparents. I'm still close to my grandmother, who's a hundred and three years old. But when I was a high junior in high school, my grandfather was driving me home from a swimming practice. I was thinner, fitter and more athletic at that point in my life, and he made the world 's slowest left hand turn and we were broadsided. So luckily no one was hurt. But I remember because I was sixteen at the time and just learning how to drive us, Grandpa, what happened? And he's like, oh, the car didn't react. Or, you know, he was blaming the car. And I didn't think much of it because, you know, I was sixteen years old. Sometime after that he was at work, and he was a greaser. So, he would climb through the machines at Colgate Palmolive and keep them all moving. And so, he was at work and he fell off a ladder and then broke his ribs. And in the emergency room, when my grandmother went to pick him up, the ER doctor turned to her and said, how long has your husband had Parkinson's disease? And she's like, what are you talking about? And then that was the first time that all of us had noticed his rest tremor. And the reason he turned the wheel so slow is because he was Bradykinetic. And so then over the next few years, he progressed in his motor symptoms. And then as I got into college, he developed the cognitive symptoms. And so, by the time I had finished medical school that was doing my residency, he was no longer oriented to time. So that even though I had finished medical school, I was in my neurology residency, I was married and with children, I was still in college at that time for him. So, he would always ask me, you know, have I heard anything from getting to medical school and the like. So, I got to watch this person who I grew up with go through all of the different stages of disease. And then eventually he developed lots of hallucinations. And although he was relatively immobile, he experienced a hallucination and jumped out of his chair, fell down, and broke his hip. And so, he underwent a hip replacement, being rather severely demented, and then passed away in the rehab hospital. As I was living this with my grandparents, the one thing that my grandfather, while he could still communicate, and that my grandmother continued to say to me, you know, up until fairly recently was, you know, what are you going to do about this? You know, we're counting on you to make a difference. And so, a lot of my research is really focused on how I can make a difference for people. One, to make sure they get diagnosed properly. Two that we would have something to offer the patient and the family. And three, we can provide hope that we are actually going to come away with effective treatments to make a difference in their lives. Dr Weathers: Well, that is really inspiring. And I think you have really done that in your work. I always like to end these conversations on a hopeful note. So, what are the developments that are on the horizon in terms of diagnosis and treatment of Lewy body dementia that you are most excited about?  Dr Galvin: Well, I think there are three things that are of great interest right now. I mean, there's lots of things, but I think three things of great interest are, one, on the diagnostic side is that we now have assays that allow us to assess synuclein in body fluids and body tissues. So, we can measure synuclein seeding assays in the spinal fluid and we can visualize Lewy bodies through skin biopsies. And that's a tremendous advance because we were really, really limited otherwise to using indirect evidence, and the only indirect evidence we had was abnormalities on DAT scanning. So, we're looking at dopamine deficiencies. But as I mentioned earlier, that's very abnormal in Parkinson's disease. But in dementia with Lewy bodies, it's a little more subtle. So, the extent of dopamine degeneration in- particularly in early DLB is limited. So, you have to look very carefully. If we're not doing quantitative DAT scan imaging, then you may miss those subtle changes. So, I think that being able to directly visualize either synuclein seeding or synuclein aggregation has really changed the game. Plasma assays, blood-based biomarkers are probably a little farther away because they're- the red blood cells have a lot of synuclein and so it interferes with the ability to get a good sensitive assay. But I do think in the next couple of years we will see PET ligands that also bind  synnuclein. So, I think diagnostically we're going to be able to provide better, earlier, and more precise diagnoses. From a treatment perspective, traditionally we've just borrowed medicines from other fields to treat symptoms, but there are a number of disease-modifying trials that are ongoing. I was fortunate to be the academic PI on two very large NIH grants where we test tested disease modifying medicines. Both of those studies are fully recruited and we should get a readout toward the end of 2024 or the beginning of 2025. So very, very excited about that. I also am fortunate to be MPI an NIH grant where we're just going to be testing the first inhuman synuclein vaccine. So very, very excited about the potential to offer disease-modifying medicines and to fulfill the promise that I made to my grandma and grandpa twenty years ago. And I think the third thing is that right now there's a little bit of like an emerging controversy about developing some integrated staging paradigms between the movement disorder world and the cognitive world. And so, while those paradigms are currently published, you know, not everybody agrees with them. But I think whether I like that staging paradigm now or not, the fact that we're coming together and trying to develop some unified staging paradigms, I think, is going to make a big difference in increasing the ability for clinicians to make early diagnoses that are more precise so that we can either get people into clinical trials or into clinical treatment protocols at the earliest possible time. And that's going to make all the difference in the world for the patients and their families.  Dr Weathers: I think that was a fantastic answer. Really, all really exciting things that I think are all, I normally, I say on the horizon. I'm thinking, you know, pretty far ahead. And I think the really wonderful thing is that all of these are either here now or very, very close to being here. So, definitely a very positive way to end this discussion. Well, Jim, thank you so much for taking the time to speak with me today. Dr Galvin: Thank you. This was wonderful. I hope the listeners found this enjoyable and interesting and read the Continuum issue. I think it's going to be the latest and greatest on what we know about the dementias.  Dr Weathers: Again, thank you again, Dr Galvin, for joining me on Continuum Audio. Again, today I've been reviewing Dr James Galvin, his article on the Lewy body dementias, dementia with Lewy bodies, and Parkinson's disease dementia appears in the December 2024 Continuum issue on dementia. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Dr. Vikram Karnik and Dr. Kate Wyman-Chick discuss distinguishing prodromal dementia with Lewy bodies from prodromal Alzheimer disease and the implications for clinical practice. Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200380 

Dr. Vikram Karnik talks with Dr. Kate Wyman-Chick about distinguishing prodromal dementia with Lewy bodies from prodromal Alzheimer disease, the importance of early diagnosis, and the implications for clinical practice. Read the related article in Neurology: Clinical Practice. Disclosures can be found at Neurology.org.

In the second part of this two-part series, Dr. Jeff Ratliff and Dr. Calum Hamilton discuss the clinical criteria that listeners should look out for, indicating a subtype of mild cognitive impairment known as DLB, which could potentially progress into a full dementia with Lewy body phenotype. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499  

飛碟聯播網《飛碟早餐 唐湘龍時間》2024.08.20 週二醫療保健單元 潘懷宗的醫學新知時間 《研究指出：攝護腺肥大藥物竟能改善「神經退化疾病」》 最新研究發現，三個治療攝護腺肥大的藥物: Alfuzosin(Az；札特持續性藥效錠)、Doxazosin(Dz；可迅持續性藥效錠)及Terazosin(Tz；暢流錠)，可以降低路易氏體失智症（DLB；Dementia with Lewy Bodies）的發生風險，原因是這些藥物的副作用(次要作用；另一個作用)剛好可以對抗DLB 的致病原因。另外，研究團隊認為這些藥物也具有治療其它神經退化疾病的潛力，研究成果已於 2024年6月發表在美國神經病學會的《Neurology》雜誌上，主要/通訊作者為愛荷華大學醫學院西莫林教授/博士(Jacob Simmering)。 最常見的三種失智症為: 阿茲海默症(佔比~60%)、DLB(~15%)以及血管型失智症(10~15%)，而DLB與典型老年失智的症狀有些不同，除進行性的失智與神經精神症狀(失眠/幻覺/憂鬱)外，尚有類似巴金森氏病的運動失調症狀，如: 動作變慢、肢體僵硬、顫抖、步態不穩、容易跌倒等等，就好像是阿茲海默症與巴金森氏病的混合體。病患通常預後不佳，平均約有8年的壽命。其發生率為每年每1000人有0.5~1.6 例，由於年紀大是主要的危險因素，所以DLB的發生率將會隨著世界人口老化而增加。目前DLB的藥物治療只能緩解症狀，尚無法預防或治癒疾病，美國著名演員羅賓˙威廉斯就是罹患此疾病。 ▶ 《飛碟早餐》FB粉絲團  / ufobreakfast  ▶ 飛碟聯播網FB粉絲團  / ufonetwork921  ▶ 網路線上收聽 http://www.uforadio.com.tw ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast SoundOn : https://bit.ly/30Ia8Ti Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD Google 播客：https://bit.ly/3gCTb3G KKBOX：https://reurl.cc/MZR0K4 -- Hosting provided by SoundOn

Scrump and Drew talk about the music of Lionel Richie, Cyndi Lauper, Post Malone, Swae Lee, DJ Blyatman, DLB, Knocked Loose, Poppy, Johnny Cash, Clutch, Black Thought, Danger Mouse, and more! Hello-Lionel Richie Time After Time-Cyndi Lauper Sunflower-Post Malone & Swae Lee Kamaz-DJ Blyatman ft DLB Suffocate-Knocked Loose ft Poppy Well Alright-Johnny Cash Electric Worry-Clutch Aquamarine-Blackthought & Danger Mouse ft Michael Kiwanuka   Patreon Merchandise   Social Media: Twitter Instagram 

Welcome back to the Australian Property Investing Podcast Everything Property with your host David Hamilton. On today's episode, Dean Bowen from DLB insurance joins us to chat about Home, Contents and Landlord insurance.- How Dean got into insurance as a career when he was young.- How he decided it was time to quit the corporate world and go all in on his own.- A breakdown of Home and Contents Insurance- A breakdown of Landlords Insurance- A breakdown of Contents Insurance and what's classified as 'contents'- How to check how much you should insure your home for- How do insurance brokers get paid- What happens to your insurance policy when an insurance company folds- Home Warranty Insurance: What is it,  who does it cover and who takes the policy out?- Can you claim defects?- Other insurance policies that builders and developers should be taking out.- Plus much, much more!To get in touch with Dean and his team, head over to:https://www.dlbinsurancerisk.com.au/OR email Dean at:dean@dlbinsurancerisk.com.auCheck to see how much your property should be insured for with this calculatorhttps://insurancecouncil.com.au/consumers/calculators/Don't forget to check out the summary post on our Instagram we just posted which covers what we discuss in this chat.Facebook: http://facebook.com/everythingproperty.auInstagram: http://www.instagram.com/everythingpropertyLinkedIn: http://linkedin.com/everythingpropertyWebsite (Coming soon)Disclaimer: The topics, conversation, opinions and discussion provided in this episode  are general in nature. As a listener you should not take or use the information discussed as financial advice. Everything Property and its associates recommend that you always engage in independent financial advice before making any investment or purchasing decision.

In this episode, Dr. Hamdy El-Hakim, pediatric airway surgeon and Associate Professor at the University of Alberta, joins host Dr. Gopi Shah to review laryngeal clefts in children. First, Dr. El-Hakim describes the presentation of laryngeal clefts. Affected children have coughing fits bad enough to cause watery eyes and “blue spells.” These fits are sometimes misattributed to other airway abnormalities or GERD. Then, discussion shifts to the workup of laryngeal clefts. All patients with a suspected laryngeal cleft need a comprehensive physical exam, a risk factor assessment and a swallow assessment, most commonly a FEES. Many patients will also require a diagnostic laryngoscopy with bronchoscopy (DLB). Dr. El-Hakim advises listeners on performing this test in children. Treatment of laryngeal clefts include thickened feeds, injection laryngoplasty, or surgical repair. Finally, Dr. El-Hakim advises listeners on compassionate care for families living with this condition. --- SHOW NOTES 00:00 - Introduction 03:39 - Laryngeal Clefts in Children: Diagnosis & Classification 06:36 - Presentation of Laryngeal Cleft 12:07 - Risk Factors & Associated Conditions 21:38 - Physical Examination Insights and Diagnostic Approaches 30:15 - The Role of FEES and Modified Barium Swallow in Diagnosis 37:37 - Navigating Pediatric Swallowing Disorders: Strategies and Challenges 41:12 - The Complexities of Diagnosing & Treating Laryngeal Cleft 45:28 - Surgical Techniques & Postoperative Care 01:03:13 - Evaluating Success Post-Surgery 01:09:20 - Final Thoughts: The Impact of Pediatric Dysphagia on Families --- RESOURCES Dr. Hamdy El-Hakim's University of Alberta Profile: https://www.ualberta.ca/airway-research/iarc-team/hamdy-el-hakim.html Article demonstrating superiority of cold steel relative to laser in type I laryngeal cleft repair: https://pubmed.ncbi.nlm.nih.gov/34184769/

Dr. Jeff Ratliff talks with Dr. Chris Gibbons about the use of skin biopsies to detect phosphorylated α-synuclein in individuals with synucleinopathies such as Parkinson disease, multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure. Read the related article in JAMA.  Disclosures can be found at Neurology.org.

Una nueva interesante entrevista traen los muchachos de DLB. Escuchen la historia de este jugador de baloncesto de liga de baloncesto puertorriqueña. Reconocido por los masivos "donqueos" que hace y graba para subir a redes sociales. No se pueden perder esta entrevista con Jan Rodríguez. DALE PLAY

Hannah Hussain narrates her blog written for Dementia Researcher. Hannah's blog examines the plight of individuals with dementia in conflict zones like Gaza, shedding light on the added layers of distress they face. Dementia, particularly certain forms, such as Dementia with Lewy bodies (DLB), not only impairs cognitive abilities but also significantly influences behaviour, often leading to heightened states of distress. The inability to communicate effectively can exacerbate this distress, leaving individuals feeling anxious, fearful, and confused. In such challenging environments, the role of informal caregivers becomes indispensable. Their efforts to maintain routine, employ calming techniques, and provide comfort are vital in creating a safer space for their loved ones. The blog also underscores the importance of caregiver wellbeing, as their resilience has a profound impact on the quality of life for those with dementia, particularly during times of adversity. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-coping-with-distress-the-strength-of-caregivers/ -- Hannah Hussain is a PhD Student in Health Economics at The University of Sheffield. As a proud third generation  migrant and British-Asian, her career path has been linear and ever evolving, originally qualifying as a Pharmacist in Nottingham, then Health Economics in Birmingham. Her studies have opened a world into Psychology, Mental Health and other areas of health, and with that and personal influences she found her passion for dementia. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always looking for new bloggers, drop us a line dementiaresearcher@ucl.ac.uk -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://bsky.app/profile/dementiaresearcher.bsky.social https://www.linkedin.com/company/dementia-researcher

CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team. CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward. Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed. Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024. Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB. Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study. These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options. The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases. With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare. #proactiveinvestors #cervomedinc #nasdaq #neurodegenerative #dementia #LewyBodies #clinicaltrial #neflamapimod #biopharmaceutical #JoshuaBoger #drugdevelopment #brainhealth #healthcare #innovation #leadership #AlkeusPharmaceuticals #DLB #neuroscience #p38MAPkinase #AscenDLB #treatmentoptions #clinicalresearch #neurologicalhealth #patientcare #caregivers #medicalscience #researchanddevelopment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hablando con los muchachos desde de los bleachers, en entrevista llega Ezequiel "Zeke" Colón, talentoso jugador de baloncesto en Puerto Rico. Dialogamos con el sobre su trayectoria de deportista y sus momentos más importantes que te sorprenderán. Sin duda alguna, alguien digno de conocer. Conócelo más aquí en DLB es un mamey. ¡DALE PLAY!

During an investor conference call held on Friday February 2nd 2024, Dolby Laboratories, Inc. released their latest earnings report. CEO Kevin Yeaman discussed the company's present financial standing and forecast for the future. Addressing the future of foundational licensing revenue, he provided assurance to investors: "We aren't seeing anything that would cause us to change our FY '24 guidance for mid-single-digit declines." From the earnings call, it is understood that Dolby Laboratories perceives Dolby Atmos and Dolby Vision as key growth drivers. These technologies, catering to various entertainment sectors, enhance the consumer's audio and visual experiences. Concurrently, the company is leveraging Dolby.io, a platform providing real-time, personalized experiences to foster additional growth. Yeaman stated on the earnings call that these technologies have the potential to reach mainstream consumers, indicating the company's forward-thinking approach. In the call, Dolby Laboratories acknowledged the implications consumer electronic expenditures can have on their foundational offerings. The company recognizes the uncertainty inherent in consumer trends, yet remains committed to the pursuit of innovation and growth. As an area of strategic investment, Dolby.io demonstrates the firm's future-oriented vision. Healthy cash generation and a strong margin profile support these growth initiatives, as acknowledged on the earnings call. Based on the information available from Dolby Laboratories, the company meets financial benchmarks consistently and surpasses earnings expectations. Its emphasis on innovative technologies like Dolby Atmos, Dolby Vision, and Dolby.io, positions it competitively in the entertainment industry. Dolby appears determined to drive growth and invest in technologies that could shape the future of digital experiences; however, it's important to recognize that future success is dependent on many variable factors, including the ever-changing dynamics of the market and consumer behaviors. DLB Company info: https://finance.yahoo.com/quote/DLB/profile For more PSFK research : www.psfk.com  This email has been published and shared for the purpose of business research and is not intended as investment advice.

The latest earnings report from Dolby Laboratories, Inc. was openly discussed during the company's earnings call, led by CEO Kevin J. Yeaman. Yeaman candidly addressed the influence of the contemporary economic conditions on Dolby's operations, acknowledging the consequential recalibration of priorities by many of the company's partners and customers. Such adjustments have reportedly led to delays in forming newer partnerships and achieving design wins. Nonetheless, the earnings call illuminated beneficial aspects of Dolby's business performance, potential areas for improvement, and financial milestones, providing insights into Dolby's offerings and strategic planning. Dolby's performance for the fiscal year outpaced projections. The company reported earnings per share (EPS) at $0.65, a noteworthy increase from the estimated figure of $0.52. Encouragingly, the Q4 revenue surpassed the previous year's figure by 4%, amounting to $291 million, solidifying a substantial year-on-year growth trend. All in all, Dolby has realized an admirable 4% growth throughout 2023, reaching a total net income of $1.3 billion. In terms of revenue growth, leading performers were the Dolby Atmos, Dolby Vision, and imaging patents divisions. That said, certain markets presented challenges to Dolby with broadcast, consumer electronics, and mobile industries reporting declines due to reduced device shipments. Despite encountering headwinds, Dolby reiterates its unwavering commitment to the evolution and spread of Dolby Atmos and Dolby Vision technologies. Efforts are ongoing to motivate creators, distributors, and device manufacturers to bolster the availability and adoption of Dolby-supported content. Strategic alliances with automotive OEMs, TV manufacturers, audio equipment companies, mobile phone makers, and social media platforms play a key role in promoting Dolby's solutions. Sustained growth over the long term is a goal that Dolby is striving to ensure by capitalizing on the vitality of its encompassing ecosystem. Thanks to a broad network of creators, distributors, and manufacturers, Dolby is confident about innovating to widen the global Dolby experience reach. Even with the underlying economic uncertainties, the company is steadfast in its optimism regarding its long-term prospects, opting to focus on enhancing profit margins over sales growth, and streamlining organizational operations to hone in on high-impact activities. It's fair to say that though facing momentary slowdowns in establishing new partnerships and scoring design wins, the recent earnings report is a testament to Dolby's enduring performance, financial robustness, and robust strategic planning. By adeptly adapting to the prevailing economic environment, Dolby Laboratories intends to firmly uphold its advantageous market position as a top-tier provider of audio and imaging technologies. DLB Company info: https://finance.yahoo.com/quote/DLB/profile For more PSFK research : www.psfk.com  This email has been published and shared for the purpose of business research and is not intended as investment advice.

The guys ponder whether they are in fact the bad guys. DLB gets a new nickname. Rev Flo talks about vacation. They discuss Republican presidential debates, babies in tubes, humans getting dumber, and people with really soft hands. DLB reluctantly talks about his gains and proof of the existence of God. And there is talk of UGA football, midnight snack cheese, Leatherman tools, and parking tickets.

In this episode of BackTable ENT, Dr. Gopi Shah and Dr. Briac Thierry, Pediatric ENT at Necker Hospital for Sick Children in Paris, France, review stridor in newborns, with a special emphasis on laryngomalacia. --- SHOW NOTES First, Briac and Gopi discuss how a newborn with stridor can present. Though stridor does occur among NICU babies, most of Briac's patients are referred by outpatient pediatricians. They discuss a list of questions to ask while taking a history and emphasize the importance of assessing growth trends. In the absence of other medical problems, declining weight can suggest severe aerodigestive tract abnormality. Any pathology that narrows the airway can cause stridor: in infants, these include laryngomalacia, vallecular cysts, subglottic cysts, tracheal rings, and bilateral vocal fold immobility. Then, Briac talks listeners through his physical exam, with special attention paid to flexible fiberoptic laryngoscopy. Briac shares his tips to maximize visualization and clinician ergonomics when scoping a small child. If bilateral vocal fold immobility is suspected, Briac recommends performing a longer fiberoptic exam so that the clinician can determine whether vocal fold immobility is present at rest or due to an uncomfortable child crying. Next, Gopi and Briac differentiate between mild, moderate, and severe laryngomalacia and the indications for going to the operating room for an airway evaluation. As 20% of children with laryngomalacia have secondary airway lesions, a meticulous laryngoscopy/bronchoscopy is mandatory in these patients when a trip to the OR is required. Moving to the OR, Briac talks about his workflow when performing diagnostic bronchoscopy/laryngoscopy (DLB) to assess various causes of stridor. The episode concludes with Briac's meditations on airway surgery as a team endeavor. --- RESOURCES Briac's Necker Hospital Profile: https://www.aphp.fr/offre-de-soin/medecin/3168653/061/16 International Pediatric ORL Group (IPOG) Laryngomalacia Consensus Recommendations: https://www.sciencedirect.com/science/article/abs/pii/S0165587616300519 Pediatric Airway Channel in Paris (@voies_aeriennes): https://www.youtube.com/@voies_aeriennes

¡Mi gente! Es jueves nuevamente, y hoy los mameys de DLB les traen una muy interesante entrevista de uno de nuestros atletas pioneros. Escucha su historia y sus logros, y hasta consejos que da para esos atletas de largas distancias en el deporte rey puedan seguir. ¿Qué esperas? DALE PLAY.

Un jueves más, un episodio nuevo de DLB es un mamey. Acompaña a los muchachos por un viaje en la historia del deporte, y revive aquellos momentos que han marcado la historia en los últimos veinte años. Además, traen un nuevo prospecto boricua al cual le debes poner el ojo. Entérate de qué momentos históricos hablaron Carlos y Wilmer en este episodio. Solo debes presionar PLAY.

The guys issue some corrections, discuss their standards, and go over some RIPs. They appreciate the male form and the genetic superiority of the Loverboy family. DLB presents his vagina-forward brand of workout gear. There is talk of dog boners, queefs, and hitting bongs on mopeds.

Escucha a los muchachos de Desde Los Bleachers conversar de todo lo más reciente como si fuera un Mamey. Te traen los últimos resultados de los distintos deportes que estuvieron disputándose en la semana. Desde MLB hasta deportes de la LAI, eso y mucho más en DLB es un Mamey. ¿Qué esperas? Conviértete en un Mamey como nosotros y DALE PLAY.

We're back, Darren Lynn Bousman is back, and our special guest Katherine Vienneau is back! Where does the epic 10-part anime Saw series go after the boring and bad Saw II? Can returning director DLB step up his twisted game for this sequel? Yes, oh lord yes! Saw III is the true beginning of the Saw sequel madness!We got Jigsaw, we got Amanda, we got brain surgery, we got traps and traps for days, we got Jeff. Oh Jeff... one of the most vividly sketched characters in recent memory, wonderfully portrayed by the fully awake Angus Macfadyen. This movie is brutal, it is hilarious, it has all the makings of a horror movie marathon sleepover classic. Katherine joins us again to dive head first into the rotten pig slop trap and get into what works so well with this entry in the franchise.Join us next week on our long, long journey to Halloween with Saw IV!

For all of you that were waiting for Lil' Skweeque to take the reins, then this episode is for you. And it gets pretty weird. The guys talk about an almost SSG, drinking with Todd, and old school bathroom hand-drying technology. They debate whether it's better to get cancer in your top or your bottom. Rev Flo talks about his new bowling underwear. Dick Loverboy relives his vacation with BTS, the guys delve into ASMR, and they have a good old-fashioned laughing fit. They mourn the loss of Terry Funk and DLB provides a Tuesdays With Dick update.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.16.549189v1?rss=1 Authors: Morella, M. L., Moors, T. E., Bertran-Cobo, C., Geut, H., Udayar, V., Timmermans-Huisman, E., Ingrassia, A. M., Breve, J. J., Bol, J. G., Bonifati, V., Jagasia, R., van de Berg, W. D. Abstract: Transcription factor EB is a master regulator of genes involved in the maintenance of autophagic and lysosomal homeostasis, processes which have been implicated in the pathogenesis of GBA-related and sporadic Parkinson's disease (PD) and dementia with Lewy bodies (DLB). TFEB activation at the lysosomal level results in its translocation from the cytosol to the nucleus. Here, we aimed at investigating whether TFEB subcellular localization is altered in post-mortem human brain of aged individuals with either prodromal PD/DLB (incidental Lewy body disease, iLBD, N=3), GBA-related PD/DLB (N=9) or sPD/DLB (N=9), compared to control subjects (N=12). We scanned nigral dopaminergic neurons using high-resolution confocal and stimulated emission depletion (STED) microscopy and semi-quantitatively scored the observed TFEB subcellular localization patterns. In line with previous studies, we observed reduced nuclear TFEB immunoreactivity in PD/DLB patients compared to controls, both sporadic and GBA-related cases, as well as in iLBD cases. Nuclear depletion of TFEB was more pronounced in neurons with Ser129-phosphorylated (pSer129) aSyn cytopathology and in cases carrying pathogenic GBA variants. Interestingly, we further observed previously unidentified TFEB-immunopositive somatic clusters in human brain dopaminergic neurons and in human embryonic stem cell (hESC)-derived neurons, which localized at the Golgi apparatus. The TFEB clustering was more frequently observed and more severe in iLBD, sPD/DLB and GBA-PD/DLB compared to controls, particularly in pSer129 aSyn-positive neurons but also in neurons without apparent cytopathology. Notably, increased frequency of cytoplasmic TFEB clusters in aSyn-negative cells correlated with reduced total GBA enzymatic activity and higher Braak LB stage. In the studied patient population, altered TFEB distribution was accompanied by a reduction in overall mRNA expression levels of selected CLEAR genes, indicating a possible early dysfunction of lysosomal regulation. Overall, these findings suggest the early cytoplasmic TFEB retention and accumulation at the Golgi prior pSer129 aSyn accumulation in incidental, GBA-related and sporadic PD/DLB and indicate TFEB as potential as early therapeutic target for synucleinopathies. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Moderator: Dag Aarsland (London, United Kingdom)Guest: Laura Bonanni (Chieti, Italy)In this episode, specialist Moderator Dag Aarsland is joined by Prof. Laura Bonanni to talk about the understanding of the prodromal in dementia with Lewybodies (DLB), the role of different diagnostic methods and management of prodromal DLB.

3 of the most asked questions to bodybuilders. The Dana Linn Bailey posted her method to grow muscle. Will her ideas work for you too? Weight cap for Men's Physique & Can you out train a bad diet? TIME STAMPS BELOW It's Just Bodybuilding 224

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.12.536572v1?rss=1 Authors: Dues, D. J., Nguyen, A. P. T., Becker, K., Ma, J., Moore, D. J. Abstract: Cognitive dysfunction is a salient feature of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). The onset of dementia reflects the spread of Lewy pathology throughout forebrain structures. The mere presence of Lewy pathology, however, provides limited indication of cognitive status. Thus, it remains unclear whether Lewy pathology is the de facto substrate driving cognitive dysfunction in PD and DLB. Through application of -synuclein fibrils in vivo, we sought to examine the influence of pathologic inclusions on cognition. Following stereotactic injection of -synuclein fibrils within the mouse forebrain, we measured the burden of -synuclein pathology at 1-, 3-, and 6-months post-injection within subregions of the hippocampus and cortex. Under this paradigm, the hippocampal CA2/3 subfield was especially susceptible to -synuclein pathology. Strikingly, we observed a drastic reduction of pathology in the CA2/3 subfield across time-points, consistent with the consolidation of -synuclein pathology into dense somatic inclusions followed by neurodegeneration. Silver-positive degenerating neurites were observed prior to neuronal loss, suggesting that this might be an early feature of fibril-induced neurotoxicity and a precursor to neurodegeneration. Critically, mice injected with -synuclein fibrils developed progressive deficits in spatial learning and memory. These findings support that the formation of -synuclein inclusions in the mouse forebrain precipitate neurodegenerative changes that recapitulate features of Lewy-related cognitive dysfunction. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

After Rescission an Insurer May be Required Only to Pay an Innocent Injured Person On rare occasions bus accidents create a temptation to passengers to claim injuries as soon as it looks like insurance may apply. When the passengers on a bus insured by West Bend Mutual Insurance Company (West Bend), their injuries appeared like magic. As a result of its attempted investigation of a bus accident, West Bend moved for summary judgment and defendant Citizens Insurance Company of the Midwest's (Citizens) responded and filed a counter motion for summary judgment. In West Bend Mutual Insurance Company v. Affiliated Diagnostic Of Oakland, LLC, et al., Civil Action No. 21-cv-11007, United States District Court, E.D. Michigan, Southern Division (February 21, 2023) the USDC weighed the equities and resolved the dispute between two insurers. BACKGROUND West Bend's amended complaint states that multiple individuals (“claimants”) allege that they were involved in an automobile accident on February 3, 2020. West Bend insured Kristy's Early Childhood Development Center, Inc. (Kristy's), pursuant to which West Bend undertook to insure Kristy's solely against risks associated with the childcare business. At the time of the accident, West Bend alleged that the vehicle was not being used for the childcare business but was instead being used by a separate business entity, DLB Transportation LLC, which had held the vehicle out for hire to the claimants. West Bend determined that Kristy's had made material misrepresentations or concealed material facts when the policy was issued in so far as DLB would be using the vehicle in connection with its business. West Bend sought rescission of the policy and a declaration that the policy was void ab initio. Only one defendant appeared in this matter and now remains: Citizens is the assigned claims plan insurer for the claims arising out of the underlying accident. In its motion for summary judgment, West Bend seeks to extend rescission of the policy as to 16 natural person defendants and certain medical providers who allegedly provided services to natural person defendants. ANALYSIS Rescission Of An Insurance Policy As To Innocent Third Parties Under Michigan Law Requires A Balancing Of The Equities Rescission as to innocent third parties is not an absolute right. When two equally innocent parties are affected, the court is required, in the exercise of its equitable powers, to determine which blameless party should assume the loss. West Bend demonstrated that it did not have any notice or opportunity to discover the true use of the vehicle. An insurer has a reasonable right to expect honesty in the application for insurance. WEST BEND'S ADDITIONAL FACTORS WEIGH IN FAVOR OF RESCISSION West Bend offers two additional arguments in support of rescission. As Citizens acknowledges: West Bend urged that natural person defendants have repeatedly stonewalled and thwarted West Bend's efforts to investigate their claims and alleged injuries and that their failure to participate in this litigation has resulted in a substantial increase in time and cost for West Bend to prosecute this case. The bus passengers' refusal to participate in litigation regarding rescission of the policy as against them suggests either ambivalence or acquiescence in the relief sought by West Bend. ZALMA OPINION It was clear that the insured lied on the application and rescission was appropriate. Whether the injured and the insurer who paid their no-fault benefits - innocent of the misrepresentation - were entitled to recover. Their default and refusal to submit to an examination under oath placed the equities in favor of West Bend who had been defrauded and the 14 people on the bus who claimed injuries only after a police officer arrived made the case a classic bus jumping case that protected West Bend. --- Support this podcast: https://podcasters.spotify.com/pod/show/barry-zalma/support

In this episode, I had the opportunity to have a conversation with David Bertasio. David not only runs DLB apparel to motivate and inspire others, but he is passionate about fatherhood, manhood, and raising up a new generation of leaders. I think you're really going to enjoy this conversation. Learn more about or contact David here: https://www.instagram.com/dlbapparel/ Go pick up some apparel for Christmas here: https://dlbapparel76.myshopify.com Learn more about Be A Man here: https://linktr.ee/be_a_man_bam If you enjoyed the episode, please like, subscribe, and share with a friend!

It's a Thanksgiving miracle! The guys welcome Henry Mitchell III back to The Bunker. There is talk of Mr. Beast, Johnny Depp, space cannons, and bad morticians. The guys debate their ability to punch their way out of a coffin. There is more talk of bad artists and talking politics with your family. Dick Loverboy does his own research and encourages people to vote. Henry drops a Shit Story Glory and a tremendous turkey story. Lil Skweeque talks about the Chinese Chain-smoking Marathon Man, and that leads to a discussion of John Daly, true American Hero. The guys talk college football, the Weird Al movie, and whether DLB is actually Roku Rich.

Straight from Benzinga newsdesk, host Brent Slava brings you the market news and stocks to watch.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659Hosts:Brent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga NewsdeskMichael O'Connor Reach out to Michael at michaeloconnor@benzinga.comBenzinga Strategy Development pro.benzinga.comNFLX, BLNK, DLB, RKLB, TAOPNetflix (NFLX) - The company will report quarterly results on Tuesday of next week. Netflix has historically reported right after the closing bell, around 4:01 or 4:02 p.m. EDT.Blink Charging (BLNK) - A play on electric vehicle infrastructure. The company is a provider of electric vehicle charging services. The electric vehicle space will be in focus early next week as Tesla (TSLA) will report quarterly results on Wednesday.Dolby Laboratories (DLB) - A play on the metaverse. The company is a developer of audio and surround-sound systems for a range of applications. On Friday morning, an analyst at research shop Tigress Financial said the "creation of increasingly immersive entertainment experiences for the Metaverse will be a major upside catalyst" for Dolby.Rocket Lab USA (RKLB) - Shares were modestly higher Friday morning following news the company was selected for a contract to build solar panels for a NASA mobile rocket program. The terms of the contract were not disclosed. Find out why this specific about the terms of the contract is important on Benzinga's daily Stocks To Watch podcast. Tune in to Benzinga's Twitter around 9:30 a.m. EDT to hear more, or listen to the podcast later Friday afternoon on Spotify or Apple Podcasts.Taoping (TAOP) - One of Friday morning's momentum names. Shares were up about 10% in pre-market action despite no news. The issue is a low-float name with about 10 million shares in its float. Traders clump this stock into the group of non-fungible token (NFT) plays. We're always looking for ways to make this content better!If you have ideas for stocks we should cover or have feedback about the info or presentation, please drop us a line at newsdesk@benzinga.com or aslicoskun@benzinga.comUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Wow... isn't she lovely... Ms. Joke Silva.  A.k.A Mrs. Joke Olu-Jacobs, the wife of a veteran Nigerian actor who starred in several British television series and international films... --> READ THE BLOG POST HERE https://lolaandola.com/joke-silva-the-standard-of-the-woman-to-marry-olu-jacobs-5-tips/ --> WATCH VIDEO VERSION HERE https://youtu.be/ZeHfFrKqFm8   And whose 80th birthday was celebrated by friends and lovers around the world from Lagos Nigeria on Sunday, July 10th, 2023.   If you are looking for a wife or looking to maintain a blissful marriage long term with your wife, I have extracted 5 simple but massive tips for you to apply to your own life.   The first tip is to marry a woman whose name is Joke.     Okay... That was a joke... no pun intended. My beautiful wife's middle name is also Joke.  But the chances of you finding a Joke is slimmed to almost none.   I do have another 5 tips for you.   And I QUOTE...   "‘Wow! This is the standard of the woman I'm going to marry."    That was what Olu Jacobs told his wife of some 37+ years when he first laid eyes on this beautiful young woman who was in her early 20's at the time.   Listen.  We don't know them personally... but never mind all that... This is “couple goals”.     At least, we can see a real life example of what marriage was designed to do even in the entertainment industry which is notorious for random divorces.    Did you see my last video on Funke Akindele and JJC Akindele… Gentlemen… we have to step our game up.  These women belong to you if you can get your sh*t together.   Don't you get tired of the horrible divorce, paternity fraud, and etc stories?   Anyway, if you are struggling in dating, relationships, marriage, parenting, career etc... Consider sending me a text message with the word "HELP" to +1 (732) 517-7532 and I will see what I can do.   Let's countdown the 5 tips from Mr Olu Jacobs and Ms Joke Silva.   Tip #5 - Avoid attachments to ideology   A lot of young men these days, in response to the decline to the pride that comes with the nuclear family, are now subscribing to archaic ideologies as a quick solution.   In fact, it's a major talking point that one of the signs of unruly women is when they choose to keep their maiden name as opposed to changing to their husband's family name as the new last or surname.   While I recognize the pride attached to the culture of women changing names once they get married, there is something to say to a man who is secure in himself enough to say these words and managed to keep his home together for 37+ years.   And I'm quote...   “She is her individual.    When I met her, she was an actress known as Joke Silva, so why should marrying me deny her audience her name.    She is Miss Joke Silva, who is Mrs Joke Jacobs.    It is as simple as that.    People now begin to say all sorts. They have even written that we are separated and all sorts of stuff.    When she is working, she is Joke Silva, but she is Mrs Joke Jacobs at home,”   That was Olu Jacobs speaking to rumors in the past.  Tabloids used to be entertainment for women.     But sadly in this modern era, men would join and shame this man who actually is an example of their secret desired results.   They shame him because he chose not to have an unhealthy attachment to the ideology of his wife changing her brand name after getting married as far back as 37+ years ago in the still "traditional non-westernized" Nigeria.   You've sworn you know everything about the traditional Africans right?   Sure you should stand for something so you don't fall just for anything.  But as a man, you must know how to identify and create valid exceptions in life.  If you don't, you will suffer from your own ignorance.   Tip #4 - Make finances the least of your problems when it comes to marriage   In a few Instagram posts on July 10th, 2023, you can see Ms. Joke Silva fitting her husband, visually appearing to be in his old age but also sick with a condition called Dementia with Lewy bodies.   Dementia with Lewy bodies (DLB) is a type of progressive dementia that leads to a decline in thinking, reasoning and independent function.   Many young man today are stupidly concerned about how much weight a lady gains after having the first baby when that's fundamentally an attraction issue that should have been ironed out earlier.     Others worried about superficial nonsense like if she makes more money or not... fundamentally an insecurity issue on the part of the man.   In reality, these are the least of your issues when you are doing life with a person you love and are in-love with.  Inevitably, crises will fall on you and whoever you are spending time with in life.   If you are an immature person, the easiest thing for you to do is to blame it on the closest person or things like finances, infidelity, in-laws.... but the reality is that there are deeper issues…   And Ultimately… you do not know tomorrow… but yet acting like God.   Focus on finding a wife... a good thing... someone you can see yourself with when you are sick and 90 years olds... flat boobs, wrinkle... and all.... provided you feel a physical attraction to them today.   Anxiety about tomorrow and yesterday will destroy and rob you of your chances of achieving true joy.   Clearly... Olu Jacobs is reaping what he sowed over the last 37 years and most likely beyond.   Tip #3 - Leverage your work and reputation to do the bragging for you.   When Aunty Joke first met Uncle Olu at a rehearsal around 1981, she had heard a lot of good things about him... “a man coming from England to play the lead role.”   The anticipation and excitement about a person she had never met... she looked forward to meeting him.   In this time and age, there are many men of all ages sadly roaming around social media creating reputations of polar opposite.     Many ladies are pinged into online and social media spaces to hear how some men have chosen to address women in disrespectful, generalized and rude manners.   That's also a form of reputation right?   Well, Law 5 of the 48 laws of power by Robert Greene says "So Much Depends on Reputation — Guard It with Your Life."   Question of the day: Do you think Mr Olu Jacobs' reputation that worked ahead of him made it easier for him to woo a fine lady like Ms Joke Silva or it didn't matter what type of reputation it was?   Answer me in the comment area below.    Tip #2 - Forgive yourself and move forward.   When they first met, here was his first statement and I quote...  "Wow! This is the standard of the woman I'm going to marry."   Ms Joke Silva thought it was a rubbish pick up line.  But she said, he continued to demonstrate being a "wonderful" person during the rehearsals.    She thought he realized... and I quote... "He had made a faux pas and tried to get in my good graces after that. And we became excellent friends."   I would argue that he confidently forgave himself as fast as humanly possible if at all necessary and moved on to demonstrate self-respect, self-validation, high self-esteem which in turn made her feel safe and secure around him.   Does a typical woman feel safe and secure around you after running your mouth online?  I am not talking about the women advocating for men's rights online.   Are you attracting the S.I.G.N language from the typical woman and having a hard time holding yourself accountable?   Shame, Insults, Guilt, Need to be right… Nagging.  Or maybe… you are the first to beat the ladies to the S.I.G.N language… “these 304s ain't sh*t!”   What I observe these days are a bunch of young men who need external validation in order to remain in their masculine frame; an oxy-freaking-moron.     They need the modern woman to be checked and roasted constantly; needy behavior.   Tip #1 - Leverage her feminine energy   The feminine energy is there ready to receive, multiply and reciprocate back to you.  It's like the ocean with a massive chaotic-like trend.  If you attempt to swim against it, you will drown yourself.   That's a whole series of processes, it takes time and that whole phenomenon and the respect that comes with it will be earned; no exceptions.  Yes! The beautiful feminine energy is conditional.   The conditions and passing the non-intentional and endless shit tests from women overall is what makes you a man.     If you have problems with this reality, you will attempt to "fake-masculine" and demand respect and you will fall flat on your face all bruised up 100% of the time.   Feel free to try and prove me wrong.   In no way, shape or form am I asking you to engage an unruly or disrespectful woman and attempt saving her, you will fail.     But I will continue to hold you accountable for engaging unruly or disrespectful community of women and attempting to save them.   It's a YOU problem.  Stop the cap and Fix YOU!

The guys come together to wonder if it is hot enough for you. They talk about ice cream, beef n cheese, a little politics, and Baker's Math. DLB talks about an upcoming DJ gig. There is also talk of pet store sexy time, Amish villains, and defending oneself against cats.

LourAfterHours' Midweek Mensches presented by @BlueWirePods - Something Personal with Mayor Matt Mayor Matt pays tribute to David Samson by going solo and unedited to discuss his fandom of David Samson, DLB show highlights, meteorology and the Michele Tafoya interview. #LourAfterHoursCrew - #MidweekMensches:  @SantiniMatt  Learn more about your ad choices. Visit podcastchoices.com/adchoices

The guys open with the major announcement that Ozzy Osbourne has Covid, which opens the door for Jon's palsy humor. They talk about the Oscar slap, bowling etiquette, and pooping in the woods. Rev Flo gets a new nickname. There is talk of coffee, Man Milk, and carpenter bees. There is a tremendous Truth Social update. DLB renames the movie “Contact,” and the guys offer a content warning.

Dayna Staggs grew up and lived in Europe for 11 years. Living stateside in 1979. Before moving abroad I lived in Ft. Campbell Kentucky and Clarksville TN for a while. Then we moved to Giesen Germany and later moved to Frankfurt, Germany. I attended middle school, high school, and college at University of Maryland in Munich Germany obtaining my college education in international business law and fine arts.   While in Europe Dayna traveled across all European countries. His first experience in music winning a Jr. High school talent contest in Frankfurt. Winning first place as performer and singer.   Today, Dayna is an Entrepreneur and Entertainment Attorney representing Rap Legends who built the hip hop billion-dollar business with classy videos, old school pioneers Kool Moe Dee, Sequence, Angie Stone, Mr. Cheeks, DLB of the Fearless Four, Kurt's Blow, Late Biz Markie Estate, and artists are known Entrepreneurs, Ja Rule, and international business owners. Mr. Staggs owns DS Global Ltd International & Associates LLC. And Litigated for artists and songwriter rights since 2008.   To contact Dayna, visit: https://www.daynaspublishing.com   Welcome to Profiles in Success and thank you for listening!   For more visit: https://profilesinsuccess.com/ Work with us: https://www.bernhardtwealth.com/

Dick Loverboy has been rolling with an illegal ball! The Rev asks dumb questions. Lil' Skweeque takes a hard stance on walking and reading. DLB is over Ukraine. The guys issue a Goldie Hawn challenge and debate the proper amount of penis on television. They talk about sodomy laws, the death penalty, and hanging meat. And Lil' Skweeque tries to convince everyone that it is actually difficult to take a life.

The guys discuss the disappearance of friend and podcasting legend Will Kiser, the war in Ukraine, and Armageddon Afterparty's recent foray onto Truth Social (we're waitlisted). Dick shares some sweet Ketamine memories and talks about bowling. They give respect to Hank the Tank and debate the merits of being the King. Rev offers a to-go food tip, DLB cracks cats' tails, and that's pretty much the entire episode.

Mujonak más dolga akadt, így megint ketten navigáltuk a DLB-t, de így is eljutottunk Ausztáliába, és a Fülöp-szigetekre is. És hogy mit kell kicsillagozni? Az adásból minden kiderül! Show notes

Mujo és Charlie mindenféle versenyeken indulgatnak, az öreg pedig unokázik amikor jön a riadókürt hangja a DLB-n. Hadüzenetet kapunk. Egy új kategóriával akarják megmenteni az életünket, amit jó, ha mindenki ízlelgetni kezd: ALACSONY-KOCKÁZATÚ-CIGARETTA. Show notes

The terminology: Dementia with lewy bodies (DLB) in United Kingdom, also known as Lewy body Dementia (LBD) in United States. Lewy body dementia is the second most common type of Dementia in the world. In American, 1 million people have Lewy body Dementia. Physician and health educator, Dr. Ngozi Onuoha discusses Dementia with lewy bodies. #Dementia #LewyBodyDementia #Health4NaijaPodcast This podcast is for education content and not medical advice. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/health4naija/support

In this episode, we'll discuss how CBD helps alleviate anxiety, improve memory function, & other benefits that may help in the prevention or treatment of Alzheimer's. CBD is now being studied for: Vascular Dementia, Dementia w/ Lewy bodies (DLB), Parkinson's, Frontotemporal dementia, & Huntington's disease. #ProtectTheHemp #TheCBDEdShow Find out more: https://cannafyl.com/blog/the-alternative-to-your-prescription-cocktail/